Insmed sells its assets to save itself
This article was originally published in Scrip
Executive Summary
How much would Merck & Co have paid if Insmed wasn't in financial dire straits? And with a multitude of biotechs having less than six months of cash, has Merck just started the big pharma bailout of the ailing biotech industry?